McClellan Urges Rigor In Pharmacogenomic R&D: Less Art, More Science
This article was originally published in The Gray Sheet
Executive Summary
Linking microarray results to clinical outcomes will provide a more stable scientific platform for product development, FDA Commissioner Mark McClellan emphasized during an inaugural speech at the National Cancer Institute Director's Seminar Series